J5P-MC-GZRA: A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants Who Have Obstructive Sleep Apnea and Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (ATTAIN-OSA); J5P-MC-GZ01: Participants with OSA unable or unwilling to use PAP therapy; J5P-MC-GZ02: Participants with OSA on PAP therapy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515905-25-00

Acronym

J5P-MC-GZRA

Enrollment

118

Registered

2025-01-14

Start date

2025-01-29

Completion date

Unknown

Last updated

2025-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overweight or Obesity, OSA (Obstructive Sleep Apnea)

Brief summary

Change from Baseline in Apnea-Hypopnea Index (AHI) [Time Frame: Baseline to Week 52]

Interventions

DRUGPlacebo to match LY

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change from Baseline in Apnea-Hypopnea Index (AHI) [Time Frame: Baseline to Week 52]	—

Countries

Czechia, Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026